Myomo (MYO) A.G.P.'s Annual Virtual Healthcare Conference summary

Market opportunity and product overview

• Developed a proprietary, FDA-registered orthotic arm brace for stroke survivors with chronic arm paralysis, addressing a large unmet need in the U.S. and globally.

• Over 3,000 devices delivered, generating approximately $40 million in revenue last year.

• Medicare coverage and increasing in-network payer contracts have expanded the addressable market.

Sales channels and reimbursement

• Devices are provided through orthotics/prosthetics practices and a direct provider business, with Medicare setting a fee of $68,800 for the primary device.

• Over 95% of volume comes from the MyoPro Motion G, with most costs covered by Medicare, commercial insurance, or VA.

• Medicare coverage since April 2024 has been a major inflection point, now covering 158 million lives as in-network provider.

Shift to recurring revenue and pipeline growth

• Recurring revenue sources increased from 24% to 49% in nine months, driven by the MyoConnect program targeting rehab hospitals.

• Hundreds of referrals from rehab hospitals have led to a higher quality patient pipeline and reduced customer acquisition costs.

• In Q1, 11% of pipeline adds and 16% of orders were generated by referrals.